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Omnibus or ArrayExpress databases clearly separated from the
peer-reviewed published data sets.
We can add some further suggestions. Jafari and Azuaje
(2006) surveyed publications for common statistical analyses,
tracking how various factors in experimental design are typi-
cally reported, for example, sample size and statistical power
calculations, normalization methods, one- or two-sided t-tests,
missing values, and homogeneity of variances. A similar litera-
ture survey of typical quality assessment practices and reporting
would be extremely useful. Large government-funded projects,
such as the Cancer Genome Atlas project, might serve as exam-
ples of good quality reporting. It would be interesting to see and
compare all of the unpublished data from the various Cancer
Genome Characterization Centers, in addition to the published
data. It also would be interesting to see the internal quality as-
sessments made by the National Cancer Institute or National
Center for Biotechnology Information. We also can expect mi-
croarray manufacturers to increasingly add quality control and
normalization features to their arrays and advertise their advan-
tages. As these quality assessments are built into the arrays and
processing software, the information will be incorporated into
the routine reporting of experimental results.
Allison, Cui, Page, and Sabripour (2006), in their recent re-
view of microarray data analysis methods, pointedly noted that,
“the usefulness of most QC measures is unsubstantiated and
no specific QC method has been embraced by the community.”
Progress in this area will be made by detailed comparisons of
various proposed methods, indicating the range of useful appli-
cations of each method and their relative strengths and weak-
nesses. Beyond that, further research is needed into the theoret-
ical foundations of quality assessment of high-dimensional data
sets and the interrelationships among experimental design, mi-
croarray design, data normalization, various statistical analyses,
and quality control methods. We look forward to continuing our
own research in these areas and also following the progress of
others. Finally, we anticipate that the most interesting results
will come from a deep synthesis of currently disparate investi-
gations.
ACKNOWLEDGMENTS
The authors thank Mike Wigler, Kenny Ye, Boris Yamrom,
and Mike Ronemus for helpful discussions. This work was sup-
ported by the Simons Foundation.
ADDITIONAL REFERENCES
Chanock, S. J., Manolio, T., Boehnke, M., Boerwinkle, E., Hunter, D.
J., Thomas, G., Hirschhorn, J. N., Abecasis, G., Altshuler, D., Bailey-
Wilson, J. E., Brooks, L. D., Cardon, L. R., Daly, M., Donnelly, P.,
Fraumeni Jr., J. F., Freimer, N. B., Gerhard, D. S., Gunter, C., Guttmacher,
A. E., Guyer, M. S., Harris, E. L., Hoh, J., Hoover, R., Kong, C. A.,
Merikangas, K. R., Morton, C. C., Palmer, L. J., Phimister, E. G., Rice, J. P.,
Roberts, J., Rotimi, C., Tucker, M. A., Vogan, K. J., Wacholder, S., Wijsman,
E. M., Winn, D. M., and Collins, F. S. (2007), “Replicating Genotype–
Phenotype Associations,” Nature, 447, 655–660.
Hicks, J., Krasnitz, A., Lakshmi, B., Navin, N. E., Riggs, M., Leibu, E.,
Esposito, D., Alexander, J., Troge, J., Grubor, V., Yoon, S., Wigler, M.,
Ye, K., Børresen-Dale, A.-L., Naume, B., Schlicting, E., Norton, L.,
Hägerström, T., Skoog, L., Auer, G., Månér, S., Lundin, P., and Zetterberg, A.
(2006), “Novel Patterns of Genome Rearrangement and Their Association
With Survival in Breast Cancer,” Genome Research, 16, 1465–1479.
Jafari, P., and Azuaje, F. (2006), “An Assessment of Recently Published Gene
Expression Data Analyses: Reporting Experimental Design and Statistical
Factors,” BMC Medical Informatics and Decision Making, 6.
Kendall, J., Liu, Q., Bakleh, A., Krasnitz, A., Nguyen, K. C. Q., Lakshmi, B.,
Gerald, W. L., Powers, S., and Mu, D. (2007), “Oncogenic Cooperation and
Coamplification of Developmental Transcription Factor Genes in Lung Can-
cer,” Proceedings of the National Academy of Sciences, 104, 16663–16668.
Lucito, R., Healy, J., Alexander, J., Reiner, A., Esposito, D., Chi, M.,
Rodgers, L., Brady, A., Sebat, J., Troge, J., West, J. A., Rostan, S., Nguyen,
K. C. Q., Powers, S., Ye, K. Q., Olshen, A., Venkatraman, E., Norton, L., and
Wigler, M. (2003), “Representational Oligonucleotide Microarray Analysis:
A High-Resolution Method to Detect Genome Copy Number Variation,”
Genome Research, 13, 2291–2305.
MAQC Consortium (2006), “The MicroArray Quality Control (MAQC) Project
Shows Inter- and Intraplatform Reproducibility of Gene Expression Mea-
surements,” Nature Biotechnology, 24, 1151–1161.
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T.,
Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., Leotta, A., Pai, D.,
Zhang, R., Lee, Y.-H., Hicks, J., Spence, S. J., Lee, A. T., Puura, K.,
Lehtimäki, T., Ledbetter, D., Gregersen, P. K., Bregman, J., Sutcliffe,
J. S., Jobanputra, V., Chung, W., Warburton, D., King, M.-C., Skuse, D.,
Geschwind, D. H., Gilliam, T. C., Ye, K., and Wigler, M. (2007), “Strong As-
sociation of de novo Copy Number Mutations With Autism,” Science, 316,
445–449.
Wellcome Trust Case Control Consortium (2007), “Genome-Wide Association
Study of 14,000 Cases of Seven Common Diseases and 3,000 Shared Con-
trols,” Nature, 447, 661–678.
Comment
Darlene R. GOLDSTEIN
Ecole Polytechnique Fédérale de Lausanne
Institut de Mathématiques and
Swiss Institute of Bioinformatics
CH-1015 Lausanne, Switzerland
The authors provide an exceptional contribution to the grow-
ing literature on quality assessment of microarrays. Their arti-
cle emphasizes the frequently overlooked importance of quality
assessment in the analysis of microarray data and supplies in-
vestigators with important new quantitative tools to carry it out.
It is also a substantial benefit to the community that the au-
thors provide software implementing these methods to the Bio-
Conductor project. This ready availability should allow NUSE
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plots and quality landscapes to become standard tools for short
oligonucleotide microarray quality assessment.
It is clear that even within the microarray community, there
is no consensus on the meaning of “quality,” nor any agreed
upon standards prescribing quality assessment protocol. Anom-
aly detection is a sound first step in data analysis, yet it is
insufficiently recognized that different quality measures are
aimed at different aspects of quality. The measures proposed
by Affymetrix concentrate mostly on experimental noise in the
hybridizations and on the integrity of the sample RNA, whereas
the RMA-based measures focus on outliers at the level of mea-
sured expression (Jones et al. 2006). The issue becomes the
identification of anomalies that are of interest. The determi-
nation of which artifacts matter most will depend greatly on
the measure used to quantify expression and also on the analy-
sis aims. Where inference is based on robust gene expression
measures such as RMA, then such characteristics as streaks or
small bright areas on the chip image should have little effect on
subsequent inference and thus should not be grounds for chip
exclusion (as suggested by some guidelines).
I now comment on some of the issues brought to light in the
figures and the discussion section.
Sample Quality versus Hybridization Quality (fig. D). The
fact that chip 12 is an outlier in both the A and B chips suggests
a problem in the sample rather than a hybridization artifact.
One of the first questions that investigators ask on QC failure
is whether they should attempt to rehybridize the sample. Thus
separation into hybridization artifacts and sample problems is a
useful feature of the quality assessment tools presented here.
There is a distinction between large but localized (and re-
movable) flaws and smaller but more pervasive flaws. Patterns
in the quality landscape, such as those shown in figure J, are
more suggestive of technical/experimental problems and indi-
cate that a rehybridization has a good chance of succeeding.
A more uniform distribution of outliers across the whole of the
chip would tend to signal problems with the sample, in which
case rehybridization would not be advised.
Spatial statistics also may be of use in automatic detection of
a nonuniform distribution of the weights across the chip. At a
more crude level, the chip could be divided into a set of regions
and a chi-squared goodness-of-fit test for uniformity applied.
Experimental Design Considerations (fig. F) In addition to
the dependency between quality measures and hybridization
date, these figures also show a large degree of confounding be-
tween date and mutant type. Any comparisons between mutants
hybridized on different days thus are likely to be very mislead-
ing. In principle, it should be easy to avoid this problem in the
first place by hybridizing different mutants on the same day.
This “importance of a well-designed experiment” also is em-
phasized in the conclusion section.
For practical reasons, hybridizations often are batched by
condition (e.g., mutant type), but the pitfalls of this practice
are obvious, and biologists need to be made more aware of
the risks involved in such a strategy. Many biologists are more
used to thinking of “design” as the sample size in each group,
which time points to study, and so on, and do not realize that,
for instance, the assignment of samples to hybridization days
also is an important aspect of design. These graphs might be
shown to biologists planning an experiment as a forceful argu-
ment against this type of design.
Statisticians also would do well to recognize that there often
is a trade-off between optimal design and robust design. A de-
sign that is “optimal” according to a statistical criterion may
be useless if the experiment cannot be successfully executed by
biologists. The practicalities of sample acquisition and storage,
along with the risks of mislabeling or cross-contamination, are
among the challenges facing experimentalists. Such difficulties
argue for a design that is simple enough to be properly executed.
Thus a balance must be struck that avoids as much as possible
this kind of confounding while not being too complicated logis-
tically to carry out without errors.
Unreliable Chips versus Outlier Chips (figs. G, H, and I).
I have a quibble with the terminology used in several figures,
including figure G—the authors seem to be equating “differ-
ent” (or “outlier”) with “lower quality.” Instead, maybe what is
being signaled in the plots in figure G is the fact that the nor-
malization algorithm has failed to remove the hybridization day
artifact, not that the second replicate data are “bad” and should
be removed. My interpretation of these plots is that it seems that
a more appropriate means of normalizing across the replicates
is needed. A more detailed example follows.
In their comments on figure H, the authors state that “[the
NUSE and RLE boxplots] show systematically much better
quality in Lab M than in Lab I.” Similar comparative remarks
are made with respect to figure I. Again, what are essentially
systematic differences in model fit are interpreted as “better
quality,” a value judgment that I am not sure is justified.
Would the authors propose discarding the Lab I chips (and
thus half of what must be a considerable sum of money) because
they are of worse quality? What does quality look like within a
site? It is not clear that because the model fits better to the Lab
M chips, the Lab I chips should be considered “bad.” Agreed,
the PM plots show that the Lab I chips seem to be rather brighter
than typical, but the Lab M chips, in contrast, seem somewhat
dimmer than might be expected. The model may be capturing
relatively unimportant aspects that are just different between
laboratories.
The following example demonstrates that within-study qual-
ity can appear acceptable, but when combining the chips and
then assessing quality, some of the chips become outliers. One
study uses a subset of the original St. Jude’s Hyperdip 50 HG
U95Av2 chips; the other uses a subset of chips from an ovarian
cancer study (Lancaster et al. 2006). Unlike the Pritzker two-
lab example, these studies are completely unrelated; however,
it does not seem unreasonable to use them to illustrate the point.
Figure 1 presents boxplots of PM, NUSE, and RLE for each
study analyzed separately. A notable difference between the
two studies is that for the Hyperdip 50 chips, the PM intensities
are both higher and more compressed. Within the study, there
do not appear to be any outlier chips. For the separate studies,
all chips would be judged to be of “acceptable quality.”
Figure 2 shows boxplots of the same measures derived from
a mixture of chips from both studies. All chips are used as in-
put to the probe-level model, from which subsequent quality
measures are derived. Several of the Hyperdip 50 chips are now
NUSE outliers and thus might be considered “low quality”; in
addition, the Hyperdip 50 chips in general have larger RLE.
But nothing about the chips themselves has changed—rather,
the measures have changed based on new relationships between
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(a) (b)
Figure 1. Boxplots of within-study PM, NUSE, and RLE quality measures for Lancaster (a) and Hyperdip (b) chips. No chips are obvious
outliers.
(a)
(b)
(c)
Figure 2. Boxplots of PM (a), NUSE (b), and RLE (c) quality measures for the combined set of Lancaster (gray) and Hyperdip chips. Several
Hyperdip chips are now apparent NUSE outliers, and H–C17 is a possible RLE outlier.
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REJOINDER 279
different chips. These two aspects should be somehow sepa-
rated: chips that are of low quality (i.e., unreliable) and chips
that are outliers (which may just be different rather than “bad”).
An alternative interpretation is that the Pritzer figures high-
light the need for a site effect that the normalization algorithm
has failed to provide, because it is apparent that measurements
of the same sample between the two laboratories are not at all
comparable. It is often thought that carrying out RMA on a
combined set of chips will remove such artifacts, but in general,
batch variation of some sort still persists (Goldstein et al. 2009).
This finding has great implications for combining data, either
from multisite studies or across independent studies. Some type
of additional adjustment (e.g., random effect modeling, within-
site centering and/or scaling, use of relative measures) is re-
quired to make the data combinable.
Artifacts in Quality Landscapes (fig. J). Here a different
meaning of the term “poor quality” is used. These figures show
several types of artifacts, but most of these are not appar-
ent in the numerical summaries introduced in the article and
thus seem unlikely to be problematic if included for down-
stream analysis. In preprocessing sets containing these chips,
I found that J5 is not a NUSE outlier but has a noticeably larger
IQR(RLE), and that J6 and J7 are both NUSE and RLE outliers.
But J1, J2, J3, J4, and J8 are neither NUSE nor RLE outliers.
Clearly, the hybridizations are not perfect, but are they truly
“poor quality,” and should they be removed or rehybridized?
Rehybridization is not without problems either, because a dif-
ferent hybridization date is potentially a new artifact.
Use of Quality Information. In the discussion section, the
authors state that “it remains an open question how to use this
kind of assessment beyond the detection and classification of
quality problems.” Some of the possibilities here include rec-
ommendations for when it may be advisable to rehybridize a
failed sample, guidelines on when to remove chips, and ex-
amination of strategies involving selective downweighting or
removal of probesets from downstream analysis. Even for the
“triangle” chip (fig. J7), most of the area of the chip is not af-
fected. Thus one might still be able to use the information by
weighting expression measures in downstream analysis (e.g.,
by estimated variances or effective number of probes).
Robust Downstream Analyses. In the conclusion section,
the authors also propose that “when there is uncertainty about
whether or not to include a chip. . . we can do both analyses
and compare the results.” In light of their reliance on robust
methods throughout, it is curious that they stop short of recom-
mending a robust approach to the downstream analyses as well.
In smaller experiments (e.g., three treatment vs. three control
subjects), robust methods of analysis of preprocessed data may
not be an option. But for larger experiments, in the case where
the outliers are not themselves of direct interest, outlier accom-
modation through robust procedures should be considered.
It is also worth noting that even chips that are of “good qual-
ity” overall are likely to have some probesets for which the ex-
pression measure is “bad quality.” Robust methods of analysis
at the single-gene level would seem to provide a straightforward
way to handle this situation.
Standards for Quality Assessment. Many statisticians have
made a call for systematic quality experiments, because such
studies will provide valuable empirical information that can aid
the diagnosis of problems and can be used for quality decisions.
But such studies are an extravagance for most experimental lab-
oratories, because chips are not cheap enough to use for this
purpose. A concerted effort is needed to obtain sufficient fund-
ing, as well as to coordinate the planning and execution of such
studies.
I wholeheartedly agree with the authors’ statement that
standards must be developed by the community. Care must
be taken to ensure that the recommended quality standards
are sufficiently dependable and suitable for long-term use,
so that practices of questionable utility do not become in-
grained. One large-scale attempt at developing standards is the
MAQC project, described at http://www.fda.gov/nctr/science/
centers/toxicoinformatics/maqc/. A fundamentally sound qual-
ity assessment framework is needed for standards development,
and the exemplary approach that the authors detail in this article
represents an important step in the proper direction.
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Rejoinder
Julia BRETTSCHNEIDER, François COLLIN,
Benjamin M. BOLSTAD, and Terence P. SPEED
We are most grateful to the editors of Technometrics for pro-
viding such an excellent platform to discuss quality assess-
ment and control for microarray data. This opportunity helps
us to bring the statistical challenges that have emerged with
the development of new genomic technologies to the close at-
tention of leading applied statisticians. Furthermore, we are
most grateful to the editors for inviting so many fine statis-
ticians to comment on our article. We are impressed by the
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